Specifically, on September 30, 2013, the Company disclosed it received a response from the U.S. Food and Drug Administration on the clinical hold already in effect since June 2013, related to sovaprevir, Achillion's NS3 protease inhibitor.
http://www.businesswire.com/news/home/20130930006619/en/Wolf-Haldenstein-Announces-Investigation-Achillion-Pharmaceuticals
http://www.businesswire.com/news/home/20130930006619/en/Wolf-Haldenstein-Announces-Investigation-Achillion-Pharmaceuticals
No comments:
Post a Comment